[go: up one dir, main page]

RU2019121698A3 - - Google Patents

Download PDF

Info

Publication number
RU2019121698A3
RU2019121698A3 RU2019121698A RU2019121698A RU2019121698A3 RU 2019121698 A3 RU2019121698 A3 RU 2019121698A3 RU 2019121698 A RU2019121698 A RU 2019121698A RU 2019121698 A RU2019121698 A RU 2019121698A RU 2019121698 A3 RU2019121698 A3 RU 2019121698A3
Authority
RU
Russia
Application number
RU2019121698A
Other languages
Russian (ru)
Other versions
RU2759952C2 (ru
RU2019121698A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019121698A publication Critical patent/RU2019121698A/ru
Publication of RU2019121698A3 publication Critical patent/RU2019121698A3/ru
Application granted granted Critical
Publication of RU2759952C2 publication Critical patent/RU2759952C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
RU2019121698A 2016-12-14 2017-12-13 Cd8a-связывающие домены типа iii фибронектина RU2759952C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662434017P 2016-12-14 2016-12-14
US62/434,017 2016-12-14
PCT/US2017/065973 WO2018111973A1 (fr) 2016-12-14 2017-12-13 Domaines de fibronectine de type iii se liant à cd8a

Publications (3)

Publication Number Publication Date
RU2019121698A RU2019121698A (ru) 2021-01-15
RU2019121698A3 true RU2019121698A3 (fr) 2021-04-22
RU2759952C2 RU2759952C2 (ru) 2021-11-19

Family

ID=62488453

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019121698A RU2759952C2 (ru) 2016-12-14 2017-12-13 Cd8a-связывающие домены типа iii фибронектина

Country Status (11)

Country Link
US (4) US10626165B2 (fr)
EP (2) EP3554562A4 (fr)
JP (1) JP7104703B2 (fr)
KR (1) KR102568559B1 (fr)
CN (1) CN110225770B (fr)
AU (1) AU2017378226A1 (fr)
BR (1) BR112019012154A2 (fr)
CA (1) CA3046963A1 (fr)
IL (1) IL267140B2 (fr)
RU (1) RU2759952C2 (fr)
WO (1) WO2018111973A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4411378A3 (fr) 2013-03-13 2024-10-23 Imaginab, Inc. Constructions de liaison à l'antigène pour cd8
JP7026613B2 (ja) 2015-08-07 2022-02-28 イマジナブ・インコーポレーテッド 標的分子に対する抗原結合コンストラクト
WO2018111978A1 (fr) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Domaines de fibronectine de type iii à liaison au cd137
WO2018111973A1 (fr) * 2016-12-14 2018-06-21 Janssen Biotech, Inc. Domaines de fibronectine de type iii se liant à cd8a
US10597438B2 (en) 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
WO2020154363A1 (fr) * 2019-01-23 2020-07-30 The Rockefeller University Protéine de fusion nucléobindine 1-immunoglobuline génétiquement modifiée
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
CN114786682B (zh) 2019-10-14 2024-07-16 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
CA3161723A1 (fr) * 2019-12-18 2021-06-24 Karyn O'neil Domaines de fibronectine de type iii se liant a la serum-albumine et leurs utilisations
BR112023021318A2 (pt) 2021-04-14 2023-12-19 Aro Biotherapeutics Company Conjugados de domínio fn3-sirna e usos dos mesmos
AU2022258566A1 (en) 2021-04-14 2023-10-12 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains
WO2025160147A1 (fr) * 2024-01-22 2025-07-31 Colorado State University Research Foundation Mutation d'aux/iaa dégron conférant une tolérance à des herbicides à base d'auxine synthétique

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ATE168416T1 (de) 1989-10-05 1998-08-15 Optein Inc Zellfreie synthese und isolierung von genen und polypeptiden
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
EP0580737B1 (fr) 1991-04-10 2004-06-16 The Scripps Research Institute Banques de recepteurs heterodimeres utilisant des phagemides
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
AU672794B2 (en) 1992-05-07 1996-10-17 Affitech As Immunoglobulin binding proteins derived from L protein and their uses
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5691157A (en) 1995-10-24 1997-11-25 The Research Foundation Of State University Of New York Method for detecting a mammal's prior exposure to radiation or radiomimetic chemicals
US5846456A (en) 1996-01-17 1998-12-08 National Science Council Method of making gradient index optical element
EP2380906A2 (fr) 1997-06-12 2011-10-26 Novartis International Pharmaceutical Ltd. Polypeptides anticorps artificiels
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
PT1015576E (pt) 1997-09-16 2005-09-30 Egea Biosciences Llc Metodo para a sintese quimica completa e montagem de genes e de genomas
US6846655B1 (en) 1998-06-29 2005-01-25 Phylos, Inc. Methods for generating highly diverse libraries
EP1137941B2 (fr) 1998-12-10 2013-09-11 Bristol-Myers Squibb Company Echafaudages de proteines pour des mimes d'anticorps et autres proteines de liaison
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
AU7072700A (en) 1999-08-23 2001-03-19 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
US20130226834A1 (en) 2000-04-27 2013-08-29 Networth Services, Inc. Systems and methods for determining the financial status of bonds
NZ522844A (en) 2000-06-28 2005-02-25 Brigham & Womens Hospital PD-L2 molecules: novel PD-1 ligands and methods to identify compounds to modulate T cell activation
JP2004526419A (ja) 2000-10-16 2004-09-02 フィロス インク． 抗体模倣物および他の結合タンパク質のためのタンパク質骨格
WO2002086083A2 (fr) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Procedes d'amelioration de la capacite de reaction de cellules t
GB0119476D0 (en) 2001-08-09 2001-10-03 Novartis Forschungsstiftlung Z Anti-tumour agents and method of identifying anti-tumour agents
EP1283053A1 (fr) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibiteurs de l'activité de HER3
JP4602614B2 (ja) 2001-09-26 2010-12-22 アイシン精機株式会社 自動車用ドア
WO2003037365A1 (fr) 2001-11-01 2003-05-08 The Johns Hopkins University Procedes et compositions pour traiter la fuite vasculaire au moyen du facteur de croissance hepacytotaire
AU2003243436A1 (en) 2002-06-06 2003-12-22 Shohei Koide Reconstituted polypeptides
CN100351375C (zh) 2002-09-06 2007-11-28 伊索杰尼卡有限公司 体外肽表达文库
AU2003275372A1 (en) 2002-09-30 2004-04-19 Compound Therapeutics, Inc. Methods of engineering spatially conserved motifs in polypeptides
JP2006523090A (ja) 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
US7407660B2 (en) 2003-04-16 2008-08-05 Genentech, Inc. Methods and compositions for selective modulation of vascularization
US8609830B2 (en) 2003-05-16 2013-12-17 Merck Sharp & Dohme Corp. Methods and compositions for RNA interference
JP4731324B2 (ja) 2003-08-28 2011-07-20 武 今西 Ｎ−ｏ結合性架橋構造型新規人工核酸
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
AU2004286261B2 (en) 2003-10-27 2010-06-24 Merck Sharp & Dohme Llc Method of designing siRNAs for gene silencing
CN1946417A (zh) 2003-12-05 2007-04-11 阿德内克休斯治疗公司 2型血管内皮生长因子受体的抑制剂
US20080220049A1 (en) 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
US20060040278A1 (en) 2004-01-27 2006-02-23 Cojocaru Gad S Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer
US7932026B2 (en) 2004-06-04 2011-04-26 Genentech, Inc. EGFR mutations
US7736647B2 (en) 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
CA2612241C (fr) 2005-07-01 2018-11-06 Medarex, Inc. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
JP2009523460A (ja) 2006-01-24 2009-06-25 ドマンティス リミテッド Ｉｌ−４および／またはｉｌ−１３に結合するリガンド
US7972785B2 (en) 2006-01-24 2011-07-05 Industrial Technology Research Institute (Itri) Biomarkers for liver fibrotic injury
CA2647671A1 (fr) 2006-03-31 2007-11-01 Massachusetts Institute Of Technology Traitement de tumeurs exprimant les recepteurs mutants de l'egf
FR2903987B1 (fr) 2006-07-21 2012-12-21 Centre Nat Rech Scient Nouveaux derives de cyclodextrines amphiphiles, leur utilisation dans les domaines pharmaceutiques,cosmetiques, alimentaires et leur application a la production de nouveaux nanosystemes
EP2121743B1 (fr) 2006-11-22 2015-06-03 Bristol-Myers Squibb Company Substances thérapeutiques à base de protéines modifiées ciblées sur des récepteurs de tyrosine kinases, dont l'igf-ir
US8536113B2 (en) 2006-12-21 2013-09-17 Janssen Biotech, Inc. EGFR binding peptides and uses thereof
JP2010523595A (ja) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
CA2683559C (fr) 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methodes de traitement d'un cancer resistant a des agents therapeutiques anti-erbb
US20080260738A1 (en) * 2007-04-18 2008-10-23 Moore Margaret D Single chain fc, methods of making and methods of treatment
ES2310122B1 (es) 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
US20090042906A1 (en) 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
WO2008156642A1 (fr) 2007-06-15 2008-12-24 Vasgene Therapeutics, Inc. Échafaudages de liaison antigène non-immunoglobuline pour inhiber l'angiogenèse et la croissance tumorale
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
JP5781762B2 (ja) 2007-08-10 2015-09-24 プロテリックス、インク ユニバーサルｉｉｉ型フィブロネクチン結合ドメインのライブラリ
ES2533874T3 (es) 2007-10-31 2015-04-15 Medimmune, Llc Armazón proteico
EP2231195B1 (fr) 2007-12-04 2017-03-29 Arbutus Biopharma Corporation Lipides de ciblage
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
AU2008345674A1 (en) 2007-12-19 2009-07-09 Centocor, Ortho Biotech Inc. Alternative scaffold protein fusions phage display via fusion to pIX of M13 phage
EP2231870A4 (fr) 2007-12-19 2011-01-26 Centocor Ortho Biotech Inc Vecteurs de phages de synthèse destinés à la conception et à la génération d'une banque de phages protéines ou peptides non anticorps humains par fusion au pix du phage m13
EA201000979A1 (ru) 2007-12-27 2011-02-28 Новартис Аг Улучшенные связывающие молекулы на основе фибронектина и их применение
JP2011517314A (ja) 2008-02-14 2011-06-02 ブリストル−マイヤーズ スクイブ カンパニー Ｅｇｆｒに結合する操作されたタンパク質に基づく標的化された治療薬
JP2011513427A (ja) 2008-03-06 2011-04-28 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ及びＥＧＦＲアンタゴニストの併用療法
CL2009000843A1 (es) 2008-04-11 2009-07-24 Galaxy Biotech Llc Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet.
PL2274331T3 (pl) 2008-05-02 2014-04-30 Novartis Ag Ulepszone cząsteczki wiążące oparte na fibronektynie i ich zastosowanie
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
WO2010036959A2 (fr) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Anticorps anti-pd-1, pd-l1, et pd-l2 humains et leurs utilisations
CA2738583A1 (fr) 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methodes de traitement du cancer
US8394924B2 (en) 2008-10-23 2013-03-12 Massachusetts Institute Of Technology Directed engagement of activating Fc receptors
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
KR101781907B1 (ko) 2008-10-31 2017-09-26 얀센 바이오테크 인코포레이티드 파이브로넥틴 타입 ⅲ 도메인 기반 스캐폴드 조성물, 방법 및 용도
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
SMT202400136T1 (it) 2008-12-09 2024-05-14 Hoffmann La Roche Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t
EP2393835B1 (fr) 2009-02-09 2017-04-05 Université d'Aix-Marseille Anticorps contre pd-1 et anticorps contre pd-l1 et leurs utilisations
RU2562700C2 (ru) 2009-02-12 2015-09-10 Янссен Байотек, Инк. Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii
WO2010115202A2 (fr) 2009-04-03 2010-10-07 Dicerna Pharmaceuticals, Inc. Procédés et compositions utilisables pour l'inhibition spécifique du gène kras par de l'arn double brin à extrémités franches
JP5612663B2 (ja) 2009-04-07 2014-10-22 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ＥｒｂＢ−１／抗ｃ−Ｍｅｔ抗体
RU2533758C2 (ru) 2009-07-07 2014-11-20 Сименс Акциенгезелльшафт Устройство и способ для измерения многофазного потока флюида
US20120270797A1 (en) 2009-08-13 2012-10-25 Massachusetts Institute Of Technology Engineered proteins including mutant fibronectin domains
KR101237036B1 (ko) 2009-11-04 2013-02-25 성균관대학교산학협력단 안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 ｓｉＲＮＡ 구조 및 그 용도
EP3279215B1 (fr) 2009-11-24 2020-02-12 MedImmune Limited Agents de liaison ciblés contre b7-h1
US8961977B2 (en) 2010-02-12 2015-02-24 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
BR112012022672B1 (pt) 2010-03-10 2020-04-14 Genmab As anticorpo monoclonal, sequência de nucleotídeos, vetor de expressão, célula hospedeira procariótica recombinante, composição farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, para detectar a presença de c-met em uma amostra, e, kit para detectar a presença de c-met em uma amostra
WO2011130328A1 (fr) 2010-04-13 2011-10-20 Medimmune, Llc Échafaudages multimères spécifiques de trail r2
BR112012026766B1 (pt) 2010-04-20 2021-11-03 Genmab A/S Métodos in vitro para gerar um anticorpo igg heterodimérico, para a seleção de um anticorpo biespecífico, vetor de expressão, anticorpo igg heterodimérico, composição farmacêutica, e, uso de um anticorpo igg heterodimérico
ES2617777T5 (es) 2010-04-23 2022-10-13 Hoffmann La Roche Producción de proteínas heteromultiméricas
EP3103478B1 (fr) * 2010-04-30 2019-04-17 Janssen Biotech, Inc. Compositions de domaine de fibronectine stabilisées, procédés et utilisations
EP2576615B1 (fr) 2010-05-26 2016-03-30 Bristol-Myers Squibb Company Protéines d'échafaudage à base de fibronectine ayant une stabilité améliorée
CN103403027A (zh) 2010-07-30 2013-11-20 诺华有限公司 纤连蛋白摇篮分子和其库
EP2621953B1 (fr) 2010-09-30 2017-04-05 Ablynx N.V. Matières biologiques associées à c-met
WO2012094727A1 (fr) 2010-10-29 2012-07-19 The Governing Council Of The University Of Toronto Encapsulation par lipides de nanoparticules pour diffusion raman exaltée de surface (sers)
WO2012162418A1 (fr) 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Procédés et compositions pour ligands de ciblage hétérodimères
US20120321666A1 (en) * 2011-05-23 2012-12-20 Cooper Laurence J N T cell therapy for b cell lymphoma
US20120315639A1 (en) 2011-06-08 2012-12-13 Glenn Yaguang Deng Method and apparatus for single cell isolation and analysis
EA035150B1 (ru) * 2011-09-27 2020-05-06 Янссен Байотек, Инк. Способ получения белковых каркасов на основе фибронектинового домена типа iii с альтернативными поверхностями связывания
SMT202000561T1 (it) 2011-11-28 2021-01-05 Merck Patent Gmbh Anticorpi anti-pd-l1 e usi relativi
AU2012358238B2 (en) 2011-12-22 2017-12-07 C. Frank Bennett Methods for modulating Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1(MALAT-1) expression
CN104114704A (zh) 2012-01-05 2014-10-22 株式会社百奥尼 高效率的纳米颗粒型双螺旋寡rna结构体及其制备方法
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
MX353567B (es) 2012-05-23 2018-01-18 Univ Ohio State Composiciones de nanoparticulas de lipidos para la entrega de oligonucleotidos antisentido.
ES2670442T3 (es) 2012-05-25 2018-05-30 Janssen Biotech, Inc. Dominios de unión a albúmina de consenso no naturales
CN104736168B (zh) 2012-05-31 2018-09-21 索伦托治疗有限公司 与pd-l1结合的抗原结合蛋白
JP6403166B2 (ja) 2012-08-03 2018-10-10 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 単一抗原抗ｐｄ−ｌ１およびｐｄ−ｌ２二重結合抗体およびその使用方法
WO2014025828A1 (fr) * 2012-08-06 2014-02-13 The Regents Of The University Of California Fragments d'anticorps recombinés par génie génétique pour le ciblage et l'imagerie de l'expression in vivo de cd8
CA3139031A1 (fr) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Anticorps monoclonaux humains anti pd-l1 et procedes d'utilisation
KR102795571B1 (ko) 2012-11-21 2025-04-11 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
US9433689B2 (en) 2013-03-12 2016-09-06 The Board Of Trustees Of The Leland Stanford Junio Probes and methods of imaging non-Hodgkins lymphoma
WO2014165082A2 (fr) 2013-03-13 2014-10-09 Medimmune, Llc Anticorps et procédés de détection
EP2968587A2 (fr) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Domaines d'échafaudage à base de fibronectine liés à une sérum albumine ou fragment se liant à celle-ci
EP2999716A2 (fr) 2013-05-20 2016-03-30 F. Hoffmann-La Roche AG Anticorps anti-récepteur de transferrine et procédés d'utilisation
US20160145355A1 (en) 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
US20160303256A1 (en) 2013-09-30 2016-10-20 The University Of North Carolina At Chapel Hill Methods and compositions for self-assembly system of nanoparticles and microparticles for multi-targeting specificity
EP3057608A4 (fr) 2013-10-14 2017-10-11 Janssen Biotech, Inc. Molécules de liaison au domaine de fibronectine de type iii modifiées par la cystéine
EP3060581A4 (fr) 2013-10-25 2017-06-07 Dana-Farber Cancer Institute, Inc. Anticorps monoclonaux anti-pd-l1 et fragments de ceux-ci
MX2016007533A (es) * 2013-12-09 2016-12-14 Univ New York Composiciones y metodos para el suministro fagocitico de agentes anti-estafilococicos.
WO2015092393A2 (fr) 2013-12-17 2015-06-25 Kymab Limited Cibles humaines
PT3094351T (pt) 2014-01-15 2022-02-22 Kadmon Corp Llc Agentes imunomoduladores
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
EA034886B1 (ru) 2014-03-20 2020-04-02 Бристол-Майерс Сквибб Компани Связывающие сывороточный альбумин домены фибронектина iii типа
CA2945325A1 (fr) 2014-04-08 2015-10-15 University Of Southern California Compositions polypeptidiques avec repetitions de type iii de la fibronectine du collagene de type vii et procedes de traitement pour la fermeture et la cicatrisation de plaies
JP6666905B2 (ja) 2014-05-29 2020-03-18 スプリング バイオサイエンス コーポレーション Ｐｄ−ｌ１抗体及びその使用
WO2015195163A1 (fr) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Anticorps totalement humain anti-pd-l1
EP3164420A4 (fr) 2014-06-30 2018-05-23 Tarveda Therapeutics, Inc. Conjugués ciblés, particules et préparations associées
CN110156892B (zh) 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
IL316808A (en) 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
EP3223866B1 (fr) * 2014-11-25 2023-03-08 Bristol-Myers Squibb Company Méthodes et compositions pour radiomarquage au 18f du domaine de fibronectine iii
SG11201703760WA (en) 2014-11-25 2017-06-29 Bristol Myers Squibb Co Novel pd-l1 binding polypeptides for imaging
HUE057720T2 (hu) 2015-05-04 2022-06-28 Cytomx Therapeutics Inc Aktiválható anti-CD71 antitestek és ezek alkalmazási eljárásai
EP3291836A4 (fr) * 2015-05-06 2018-11-14 Janssen Biotech, Inc. Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci
KR102625793B1 (ko) 2015-05-06 2024-01-15 얀센 바이오테크 인코포레이티드 전립선 특이적 막 항원 결합 피브로넥틴 iii형 도메인
US10781246B2 (en) 2015-06-05 2020-09-22 New York University Compositions and methods for anti-staphylococcal biologic agents
US10426842B2 (en) 2015-07-15 2019-10-01 The Curators Of The University Of Missouri Targeted nanoparticle conjugate and method for co-delivery of siRNA and drug
CN105907719B (zh) * 2016-04-18 2019-10-18 阿思科力(苏州)生物科技有限公司 Anti ROBO1 CAR-T细胞及其制备和应用
JP7111627B2 (ja) 2016-06-03 2022-08-02 ヤンセン バイオテツク，インコーポレーテツド 血清アルブミン結合フィブロネクチンｉｉｉ型ドメイン
AU2017281083B2 (en) 2016-06-21 2022-01-27 Janssen Biotech, Inc. Cysteine engineered fibronectin type III domain binding molecules
JP7088932B2 (ja) 2016-09-14 2022-06-21 ヤンセン バイオテツク，インコーポレーテツド Ｂｃｍａ特異的フィブロネクチンｉｉｉ型ドメインを有するキメラ抗原受容体、及びその使用
US10597438B2 (en) 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
WO2018111978A1 (fr) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Domaines de fibronectine de type iii à liaison au cd137
WO2018111973A1 (fr) * 2016-12-14 2018-06-21 Janssen Biotech, Inc. Domaines de fibronectine de type iii se liant à cd8a
SG11202003864XA (en) 2017-12-13 2020-07-29 Janssen Biotech Inc Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression
US20190184028A1 (en) 2017-12-14 2019-06-20 Janssen Biotech, Inc. Targeting with firbronectin type iii like domain molecules

Also Published As

Publication number Publication date
AU2017378226A1 (en) 2019-06-20
CN110225770B (zh) 2022-04-26
US20210032312A1 (en) 2021-02-04
US11299534B2 (en) 2022-04-12
US20230143550A1 (en) 2023-05-11
IL267140B2 (en) 2023-02-01
KR20190100226A (ko) 2019-08-28
IL267140A (en) 2019-08-29
RU2759952C2 (ru) 2021-11-19
IL267140B (en) 2022-10-01
EP3554562A1 (fr) 2019-10-23
KR102568559B1 (ko) 2023-08-18
CA3046963A1 (fr) 2018-06-21
WO2018111973A1 (fr) 2018-06-21
US11932680B2 (en) 2024-03-19
EP3932432A1 (fr) 2022-01-05
BR112019012154A2 (pt) 2019-11-12
US20180162927A1 (en) 2018-06-14
JP2020513744A (ja) 2020-05-21
US10626165B2 (en) 2020-04-21
RU2019121698A (ru) 2021-01-15
CN110225770A (zh) 2019-09-10
JP7104703B2 (ja) 2022-07-21
US20240301033A1 (en) 2024-09-12
EP3554562A4 (fr) 2020-11-04

Similar Documents

Publication Publication Date Title
BR112019009389A2 (fr)
BR122021013712A2 (fr)
BR122020022459A2 (fr)
BR112019006736A2 (fr)
BR202016025584U2 (fr)
BR202016021516U2 (fr)
CN303537689S (fr)
CN303537800S (fr)
CN303535547S (fr)
CN303536129S (fr)
CN303536208S (fr)
CN303536232S (fr)
CN303536246S (fr)
CN303536269S (fr)
CN303536362S (fr)
CN303536516S (fr)
CN303536549S (fr)
CN303536736S (fr)
CN303537271S (fr)
CN303537358S (fr)
CN303537427S (fr)
CN303537519S (fr)
CN303537566S (fr)
CN303537608S (fr)
CN303539115S (fr)